Published in Cancer Chemother Rep 3 on May 01, 1973
Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice. J Clin Invest (1979) 0.80
Chlorozotocin, an anti-tumour agent lacking bone marrow toxicity at therapeutic doses: effects on lymphocyte subpopulations in mice. Clin Exp Immunol (1980) 0.79
Cytostatic action of two nitrosoureas derived from cysteamine. Br J Pharmacol (1986) 0.77
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med (1973) 1.87
Adriamycin-a review. J Natl Cancer Inst (1975) 1.68
The chemotherapy of urologic cancer. Cancer (1975) 1.32
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev (1976) 1.31
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res (1975) 1.22
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials (1980) 1.16
Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13
Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer. Cancer Chemother Pharmacol (1980) 1.11
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07
Single and combination nonhormonal chemotherapy in breast cancer. Cancer (1972) 1.06
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Glutamine antagonists in chemotherapy. Adv Pharmacol Chemother (1970) 1.01
Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer (1976) 1.00
Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99
Calibrated phase II clinical trials in oncology. Stat Med (1987) 0.99
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97
Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer (1976) 0.96
Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Combination chemotherapy of advanced Hodgkin's disease. A review. Cancer (1974) 0.91
Streptozotocin and metastatic insulinoma. Ann Intern Med (1971) 0.89
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
The nitrosoureas--thoughts for the future. Cancer Treat Rep (1976) 0.88
Investigational drugs under study by the United States National Cancer Institute. Cancer Treat Rev (1976) 0.88
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
Antiestrogens in the treatment of breast cancer. Cancer Treat Rev (1976) 0.86
Population-based study of small-cell lung cancer. J Clin Oncol (1985) 0.86
Clinical comparison of the nitrosoureas. Cancer (1975) 0.86
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (1975) 0.86
The California breast cancer law and government-mandated patient education. CA Cancer J Clin (1982) 0.86
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev (1977) 0.86
Perspectives on research in gynecologic oncology. Cancer (1976) 0.86
Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer (1973) 0.85
Cancer chemotherapy: new developments and changing concepts. Drugs (1980) 0.85
Chemotherapy in advanced breast cancer. Int J Radiat Oncol Biol Phys (1978) 0.83
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res (1972) 0.83
Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol (1984) 0.83
Gastric cancer: current status of treatment. J Natl Cancer Inst (1977) 0.83
The chemotherapy of head and neck cancer. Semin Oncol (1977) 0.83
Methyl-CCNU inclinical cancer therapy. Cancer Treat Rev (1974) 0.83
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer (1985) 0.81
New drugs on the horizon in bronchogenic carcinoma. Cancer (1972) 0.81
Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. Cancer Res (1983) 0.81
Chromomycin A3, mithramycin, and olivomycin: antitumor antibiotics of related structure. Adv Pharmacol Chemother (1975) 0.81
The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer. Breast Cancer Res Treat (1981) 0.81
Current therapies in osteosarcoma. Cancer Treat Rev (1975) 0.80
Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J Clin Oncol (1984) 0.80
New chemotherapeutic agents--bleomycin and adriamycin. CA Cancer J Clin (1975) 0.80
Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. Cancer Treat Rev (1974) 0.80
Some thoughts on experimental models and their clinical correlations. Eur J Cancer (1975) 0.80
Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial. J Natl Cancer Inst (1976) 0.80
Chemotherapy and genitourinary oncology. I. Bladder cancer. Cancer Treat Rev (1978) 0.80
Immunotherapy of cancer in man: current status and prospectus. Ann N Y Acad Sci (1976) 0.79
Single-agent therapy for Hodgkin's disease. Arch Intern Med (1973) 0.79
Methodology of data reporting in advanced breast cancer trials. Cancer Chemother Pharmacol (1979) 0.79
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer. Urology (2001) 0.78
Sequential combination of bleomycin and mitomycin in advanced cervical cancer--an American experience: a Northern California Oncology Group study. Cancer Treat Rep (1982) 0.78
Cyclophosphamide in solid tumors. Cancer Treat Rev (1975) 0.78
Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California Oncology Group and the Japanese Gastric Cancer Chemotherapy Group. Cancer (1983) 0.78
Experimental models and their clinical correlations. Natl Cancer Inst Monogr (1977) 0.77
2,2'-(9,10-anthrylenedimethylene)bis[2-thiopseudourea], dihydrochloride, dihydrate (NSC-56054)--clinical brochure. Cancer Chemother Rep 3 (1968) 0.77
C.R.O.S. conference on combined modalities chemotherapy/radiotherapy. Hilton Head Island, South Carolina, November 15--18, 1978. Cancer Chemother Pharmacol (1979) 0.77
Plant products in cancer chemotherapy. Cancer Treat Rep (1976) 0.77
Current protocol approaches in large bowel cancer. Semin Oncol (1976) 0.77
Future directions in the therapy for large bowel cancer. Cancer (1982) 0.76
Clinical considerations in the design of clinical trials. Cancer Treat Rep (1980) 0.76
Peplomycin. Cancer Treat Rev (1984) 0.76
Mitomycin C (NSC-26980)--clinical brochure. Cancer Chemother Rep 3 (1968) 0.76
Treating breast carcinoma. West J Med (1976) 0.75
Adriamycin--friend and foe. Am J Surg Pathol (1977) 0.75
Phase III studies and the strategy for integrating chemotherapy into a combined modality approach. Natl Cancer Inst Monogr (1977) 0.75
Antitumor antibiotics--thoughts for the future. Recent Results Cancer Res (1978) 0.75
Cancer chemotherapy as it approaches middle age. Cancer Chemother Pharmacol (1978) 0.75
Phase I clinical trials. Natl Cancer Inst Monogr (1977) 0.75
The clinical evaluation of analogues II. Bleomycins. Cancer Chemother Pharmacol (1978) 0.75
New drugs under clinical evaluation in the United States. Cancer Chemother Pharmacol (1978) 0.75
Planning combined therapy--the interaction of experimental and clinical studies. Cancer Chemother Rep 2 (1974) 0.75
Phase II clinical trials. Natl Cancer Inst Monogr (1977) 0.75
The analysis of adjuvant trials. Cancer Treat Rev (1978) 0.75
The strategy of cancer treatment: testicular carcinoma. Recent Results Cancer Res (1977) 0.75
Concluding remarks on malignant lymphomas. Recent Results Cancer Res (1978) 0.75
What you can do for your patients with breast cancer. Med Times (1978) 0.75
Endometrial cancer: approach to development of effective chemotherapy. Gynecol Oncol (1974) 0.75
The strategy of cancer treatment: introduction. Recent Results Cancer Res (1977) 0.75
The chemical therapy of breast cancer. Semin Oncol (1974) 0.75
Proceedings: Anticancer drug development programs: a comparison of approaches in the United States, the Soviet Union, Japan, and Western Europe. Natl Cancer Inst Monogr (1974) 0.75
Osteogenic sarcoma treatment overview and some comments on interpretation of clinical trial data. Cancer Treat Rep (1978) 0.75
Current therapy approaches of the Division of Cancer Treatment with emphasis on pancreatic carcinoma. J Surg Oncol (1974) 0.75
The clinical evaluation of analogues. I. The overall problem. Cancer Chemother Pharmacol (1978) 0.75